Emerging in the field of excess body fat treatment, retatrutide represents a different strategy. Unlike many current medications, retatrutide functions as a dual agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. This dual stimulation promotes check here several helpful ef